Tumor Microenvironment Acts As Mechanism of Resistance to Chemotherapy in Colorectal Cancer

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) in Spain have published a new Oncotarget work which highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the fourth most common cancer and the leading cause of cancer death worldwide. The article describes how the presence of certain molecules in the environment of the tumor triggers processes that protect the tumor cells from the action of conventional chemotherapy. Resistance to treatment is one of the main obstacles that patients face during the course of the disease; therefore, understand the mechanisms by which it develops is essential to improve the prognosis. The study led by Dr David G. MollevĂ­, researcher of the Program against cancer therapeutic resistance (PROCURE) of IDIBELL, reports how certain cytokines, chemokines and other soluble factors secreted by carcinoma -associated fibroblasts (CAFs), a type of normal cell which is closely associated with primary tumor cells, induce processes that slow down cell cycle, affecting the proliferation of tumor cells. In the presence of conventional chemotherapy, such factors allow stabilization and activation of selected downstream proteins that minimize the effectiveness of the treatment. However, it has also been reported that inhibition of the JAK/STAT signaling pathway, addict to many of these cytokines, might revert the process. The importance of tumor microenvironment (TME) as a relevant contributor to cancer progression and its role in the development of resistance to therapies has become increasingly apparent to researchers.
Login Or Register To Read Full Story